Loading ETF profile…
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) operates as an exchange-traded fund. Its primary aim is to mirror the financial performance—both capital appreciation and income generation—of the Nasdaq US Smart Pharmaceuticals Index, prior to any fund-specific fees and expenses. To achieve this, the ETF endeavors to precisely replicate the constituents and their proportionate allocations within that index, striving for a performance correlation of at least 95%.
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| LLY | Eli Lilly and Company | 7.90% | $2.89M |
| ABBV | AbbVie Inc. | 7.40% | $2.71M |
| MRK | Merck & Co., Inc. | 7.06% | $2.58M |
| JNJ | Johnson & Johnson | 7.03% | $2.57M |
| BMY | Bristol-Myers Squibb Company | 6.34% | $2.32M |
| BIIB | Biogen Inc. | 3.81% | $1.39M |
| VTRS | Viatris Inc. | 3.67% | $1.34M |
| CAH | Cardinal Health, Inc. | 3.48% | $1.27M |
| VRTX | Vertex Pharmaceuticals Incorporated | 3.40% | $1.24M |
| AMGN | Amgen Inc. | 3.14% | $1.15M |
| PFE | Pfizer Inc. | 2.98% | $1.09M |
| GILD | Gilead Sciences, Inc. | 2.86% | $1.05M |
| REGN | Regeneron Pharmaceuticals, Inc. | 2.73% | $997.63K |
| UTHR | United Therapeutics Corporation | 2.72% | $992.84K |
| JAZZ | Jazz Pharmaceuticals Plc | 2.43% | $889.31K |
| INCY | Incyte Corporation | 2.40% | $876.92K |
| ILMN | Illumina, Inc. | 2.03% | $740.34K |
| ZTS | Zoetis Inc. | 1.89% | $689.80K |
| EXEL | Exelixis, Inc. | 1.71% | $623.57K |
| CRL | Charles River Laboratories International, Inc. | 1.47% | $536.18K |
| MEDP | Medpace Holdings, Inc. | 1.41% | $516.54K |
| NBIX | Neurocrine Biosciences, Inc. | 1.37% | $499.63K |
| PTCT | PTC Therapeutics, Inc. | 1.36% | $496.84K |
| ALKS | Alkermes Plc | 1.35% | $492.00K |
| HALO | Halozyme Therapeutics, Inc. | 1.18% | $431.67K |